Phase 3 TRIUMPH trials are ongoing, with results expected throughout 2026
Because its insulin-boosting effect is glucose-dependent, Ozempic works for type 2 diabetes by only ramping up insulin production when blood sugar is already elevated
FDA's April 30, 2026 Proposal On April 30, 2026, the FDA announced a proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List, finding no clinical need for outsourcing facilities to compound these drugs from bulk drug substances when FDA-approved versions are available
Additionally, IL-6 infusion elevates GLP-1 in mice but not in humans, underscoring species-specific regulation of inflammation
Regulators increasingly expect explicit acknowledgment of such uncertainty and clear plans to resolve it through biomarker-driven early-phase studies, rather than relying solely on associative epidemiology
Obesity is associated with 13 types of cancer, increased surgical complication rates, lost work productivity ($1,784 per obese worker annually), and reduced life expectancy of 5 to 14 years depending on severity
